| News

First semester starts well for FHNW Campus Muttenz

20.09.2018

The semester has got off to a successful start at FHNW University of Applied Sciences and Arts Northwestern Switzerland’s new Campus Muttenz. With 4,000 students and 800 employees, the campus comprises five schools.

FHNW, Campus Muttenz (img: Ralf Dümpelmann)

This week saw the opening of Campus Muttenz, giving the FHNW University of Applied Sciences and Arts Northwestern Switzerland one campus in each of its four supporting cantons.

The new campus comprises five school: the School of Life Sciences, the School of Architecture, Civil Engineering and Geomatics, the School of Social Work, the Pedagogical School and the trinational mechatronics programme at the School of Technology. It employs around 800 staff and has some 4,000 students, according to a press release.    ​​​​

Following four years of construction and investment of around 302 million Swiss francs, the campus at Polyfeld in Muttenz has got off to a good start. With no capacity issues reported by the SBB or the regional transport authorities, the staggered start of classes proved successful.

Muttenz is FHNW’s first campus in the Basel area. The canton has the relatively largest proportion of students, at around 29 per cent, followed by the canton of Solothurn with 28 per cent, the canton of Aargau with 24 per cent and the canton of Basel-Stadt with 19 per cent. The FHNW comprises nine schools in total.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.